at position 288 and glutamic acid with lysine at position 366. The wild-type allele is denoted as PiM. We hypothesized that mutations in the SERPINA1 gene may be the cause for A1AT misfolding in PE. To test our hypothesis, we undertook this study, wherein the primary objective was to determine the frequency of PiS and PiZ mutations in the SERPINA1 gene in a cross section of preeclamptic women.
mAteriAls And metHods

Study design
We carried out this cross-sectional study by including pregnant women diagnosed with PE. The blood sample was collected from each patient and used to determine the presence of the SERPINA1 gene mutation. The study was approved by the Institutional Ethics Committee. The patients were enrolled during the period of November 2016-February 2018. All the patients provided informed consent at the time of enrollment.
Sample size
The sample size was calculated using OpenEpi version 3.01 statistical web tool (http://www.openepi.com/Menu/OE_ Menu.htm). The sample size for 99% confidence limit was found to be 196 preeclamptic patients based on the prevalence of PE in the Indian population which is ~8%. [17] 
Patient selection
The study population included pregnant women diagnosed with PE. Diagnosis criteria for PE were as follows: (i) new-onset hypertension (two readings of systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg measured 4 h apart while the patient is on bed rest; (ii) ≥20 weeks of gestation; (iii) new-onset proteinuria (˃300 mg protein for 24 h of urine or + 1 on dipstick); and (iv) in the absence of proteinuria, other symptoms such as hemolysis elevated liver low platelet (HELLP) syndrome, edema, thrombocytopenia, impaired liver function, new-onset cerebral or visual disturbances, and renal insufficiency, and in the absence of other renal diseases, nausea, severe headache, and convulsions. [2] Inclusion criteria were as follows: (i) pregnant women with PE, (ii) superimposed eclampsia, (iii) singleton and multiple gestations, and (iv) primigravida and multigravida conditions. Exclusion criteria were: (i) pregnant women with chronic hypertension and (ii) comorbidities such as diabetes mellitus, epilepsy, respiratory diseases, and heart diseases.
Genotyping of PiS and PiZ alleles of SERPINA1 gene
Blood samples were collected in an ethylenediaminetetraacetic acid vacutainer used for the isolation of genomic DNA by salting-out method. [18] Quantity and purity of the DNA samples were checked by a spectrophotometer. PiS and PiZ alleles of the SERPINA1 gene were determined by polymerase chain reaction (PCR)-restriction fragment length polymorphism method. PCR conditions are summarized in Table 1 . PCR was performed in 25-µl final volume containing 1 pM of each primer, 1-mM deoxynucleoside triphosphates, 1.5-mM MgCl 2 , 100-ng genomic DNA, and 1 unit of Taq DNA polymerase. An aliquot of the amplicon in each case was incubated at 65°C with ten units of Taqα1 restriction enzyme for 16 h, and the digestion pattern was analyzed on 3% agarose gel.
results
A total of 200 preeclamptic pregnant women meeting the inclusion criteria were included in the study. Baseline parameters and clinical outcome of the study participants enrolled in the study are listed in Table 2 . The cohort included patients of all the major clinical subtypes. Almost 56.5% of the preeclamptic women were primigravida and 43.5% were multigravida. This is in agreement with the general trend of PE being more common in primigravida than in multigravida. Nearly 47% of the preeclamptic women presented with mild type, whereas the remaining 53% showed severe type. Overall 15% of the preeclamptic patients were superimposed with eclampsia. HELLP syndrome was a rare complication that was observed only in 1% of the patients. Fetal complications in the form of intrauterine growth restriction and stillbirth were seen in 10.5% and 4% of the patients, respectively. Nearly 37.5% of the patients showed the early-onset type of PE, whereas the remaining 62.5% showed the late-onset type. All the preeclamptic patients were genotyped for PiS and PiZ mutations in the SERPINA1 gene. PiS and PiZ mutations were not observed in any of the patients either in homozygous or heterozygous conditions. discussion Protein folding is a process by which the linear polypeptide chain assumes a thermodynamically stable and a functional form. [19] Folding ensures that the hydrophobic groups are buried away in the core, whereas the charged groups are freely exposed to the surrounding aqueous medium. The collapse of the stable folding pattern leads to the loss of protein function and exposes the core hydrophobic groups to the aqueous medium. Hydrophobic interactions between the exposed core groups result in the formation of aggregates called amyloid deposits that build up in tissues. [20] Misfolded proteins are commonly observed in neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and Huntington's disease; it is also associated with conditions such as Type II diabetes and medullary carcinoma of thyroid. [21] Emerging evidence indicates that PE is a proteopathy. [4] [5] [6] [7] [8] [9] Misfolded proteins have been reported in the placenta, urine, and plasma of preeclamptic women. [4] [5] [6] [7] [8] [9] This is further supported by the demonstration of elevated activation of the "unfolded protein response (UPR)" pathway in the placenta of preeclamptic women. [22] UPR promotes protein folding by activating chaperone expression and induces apoptosis if the restoration is insufficient. We have recently shown urinary misfolded proteins equally represented in both early-and late-onset PE. [9] Major proteins identified in the urinary misfolded proteome of preeclamptic women include A1AT, ceruloplasmin, immunoglobulin-free light chains, albumin, interferon-inducible protein 6-16, and Alzheimer's β-amyloid. [6] At present, there is little information on the origins of protein misfolding in PE. Genetic involvement in the misfolding of A1AT protein is a classical textbook example. [23] Therefore, we chose to evaluate the involvement of common mutations in the SERPINA1 gene with PE. SERPINA1 gene codes for A1AT protein. A1AT is an important plasma serine protease inhibitor whose main function is to neutralize the proteolytic effect of neutrophil elastase. This enzyme facilitates infiltration of neutrophils into tissues through proteolytic degradation of extracellular matrix proteins such as elastin, proteoglycan, collagen, and fibrinogen present in the vascular basement membrane. Reduction in A1AT level disturbs the homeostatic balance between A1AT and elastase, and the excess elastase activity leads to tissue damage. Elastase-mediated tissue damage arising due to A1AT deficiency is well documented in the case of chronic pulmonary obstructive disease. [24] A1AT deficiency arises due to point mutations that lead to misfolding of the mutant enzyme. [25] However, the clinical manifestation of A1AT deficiency involves both genetic predisposition and environmental modifiers. The active oxygen intermediates produced due to cigarette smoking accelerate the severity of clinical manifestations by functionally inactivating the residual AIAT enzyme. [25] PiS and PiZ are the common mutations in the SERPINA1 gene that render A1AT prone to misfolding. These mutations cause severe A1AT deficiency when present in recessive condition. However, under the heterozygous condition, they produce borderline deficiency with little clinical manifestation. [24] Individuals who carry PiS and PiZ mutations under heterozygous conditions are at an increased risk of developing severe A1AT deficiency when exposed to compounding risk factors such as oxidative stress. For instance, heterozygous individuals per se may not develop chronic pulmonary obstructive disease but are at an increased risk when habituated to tobacco smoking. [26] We assumed that a similar interaction may be involved in the pathogenesis of PE because the involvement of oxidative stress is already well established. [27] Therefore, women who carry PiS and PiZ mutations under heterozygous conditions may not manifest any symptoms of A1AT deficiency but may be prone to A1AT misfolding during pregnancy due to oxidative stress. Another line of evidence that motivated us to choose A1AT is the consistent observation from several studies that its level is deficient in the plasma and placenta of preeclamptic women. [14, 28, 29] Furthermore, animal studies on preeclamptic mouse model have shown that intravenous injection with exogenous A1AT ameliorates PE. [14] conclusion In this study, we evaluated the frequency of PiS and PiZ mutations in the SERPINA1 gene among preeclamptic women. We found that the frequency of these mutations was zero in these women. This encourages us to conclude that common mutations in the SERPINA1 gene may not be associated with the risk of developing PE.
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